BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 7911400)

  • 1. Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview.
    Dobrilla G; Di Fede F
    Clin Ther; 1993; 15 Suppl B():2-13. PubMed ID: 7911400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. pH, healing rate, and symptom relief in patients with GERD.
    Huang JQ; Hunt RH
    Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
    Florent C
    Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
    Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Robinson M; McFarland M; Sabesin S; Lehman GA; Castell D
    Am J Gastroenterol; 1997 Mar; 92(3):429-37. PubMed ID: 9068463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term management of gastroesophageal reflux disease and its complications.
    Richter JE
    Am J Gastroenterol; 1997 Apr; 92(4 Suppl):30S-34S; discussion 34S-35S. PubMed ID: 9127624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance.
    Bardhan KD
    Yale J Biol Med; 1996; 69(3):211-24. PubMed ID: 9165690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
    Huang JQ; Hunt RH
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group.
    Feldman M; Harford WV; Fisher RS; Sampliner RE; Murray SB; Greski-Rose PA; Jennings DE
    Am J Gastroenterol; 1993 Aug; 88(8):1212-7. PubMed ID: 8101695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis.
    Baldi F; Morselli-Labate AM; Cappiello R; Ghersi S;
    Am J Gastroenterol; 2002 Jun; 97(6):1357-64. PubMed ID: 12094850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies.
    Howden CW; Henning JM; Huang B; Lukasik N; Freston JW
    Am J Gastroenterol; 2001 Jun; 96(6):1704-10. PubMed ID: 11419818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The medical management of reflux esophagitis. Role of antacids and acid inhibition.
    Sontag SJ
    Gastroenterol Clin North Am; 1990 Sep; 19(3):683-712. PubMed ID: 1977703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis.
    Earnest DL; Dorsch E; Jones J; Jennings DE; Greski-Rose PA
    Am J Gastroenterol; 1998 Feb; 93(2):238-43. PubMed ID: 9468251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
    Harris RA; Kuppermann M; Richter JE
    Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lansoprazole: a comprehensive review.
    Zimmermann AE; Katona BG
    Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lansoprazole versus omeprazole in the treatment of reflux esophagitis.
    Vcev A; Stimac D; Vceva A; Rubinić M; Ivandić A; Ivanis N; Horvat D; Volarić M; Karner I
    Acta Med Croatica; 1997; 51(3):171-4. PubMed ID: 9248117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety, and cost issues in managing patients with gastroesophageal reflux disease.
    Garnett WR
    Am J Hosp Pharm; 1993 Apr; 50(4 Suppl 1):S11-8. PubMed ID: 8097363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.
    Richter JE; Campbell DR; Kahrilas PJ; Huang B; Fludas C
    Arch Intern Med; 2000 Jun; 160(12):1803-9. PubMed ID: 10871974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic approaches to healing esophagitis.
    Boyce HW
    Am J Gastroenterol; 1997 Apr; 92(4 Suppl):22S-27S; discussion 27S-29S. PubMed ID: 9127623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of omeprazole in healing and prevention of reflux disease.
    Klinkenberg-Knol EC
    Hepatogastroenterology; 1992 Feb; 39 Suppl 1():27-30. PubMed ID: 1577392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.